Yisha Liang

Yisha Liang

Auto-generated profile, based on publicly available information

Yisha Liang

Ragon Institute of Mass General, MIT, and Harvard, 600 Main Street, Cambridge, MA 02139, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 January 2021 in Science Advances
Verified
Journal Article
Open access
PDF file
YLYisha Liang
Yisha Liang
GZGuigen Zhang
Guigen Zhang
QLQiheng Li
Qiheng Li
LHLin Han
Lin Han
XHXiaoyou Hu
Xiaoyou Hu
JZJin Zhong
Jin Zhong
A genome-wide screening revealed that TRIM26 is a host factor for HCV replication and a new determinant for host tropism.

15 October 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
YLYisha Liang
Yisha Liang
IEIsabella R. Evavold
Isabella R. Evavold
SPSepideh Parvanian
Sepideh Parvanian
MHMakiko Hayashi
Makiko Hayashi
EGEmerson Glassey
Emerson Glassey
CECharles L. Evavold
Charles L. Evavold
Pyroptosis is a lytic form of cell death executed by gasdermin pores. Through a CRISPR screen to uncover macrophage genes required for gasdermin D (GSDMD) pore activity, we identify the endosome adaptor Rabgef1 as a positive regulator of pore formation. Rabgef1 deficiency preserves NT-GSDMD membrane binding but prevents NT-GSDMD oligomerization and lytic death. Mechanistic analyses revealed that Rabgef1 deficiency is associated with an overabundance of cholesterol in the plasma membrane. Cholesterol depletion or redistribution through multiple approaches restores GSDMD oligomerization and pyroptosis. The Rabgef1-mediated control of membrane cholesterol and pore formation was found to be a general regulator of the gasdermin family. In cancer cells, organoids, and tumors, cholesterol reduction sensitizes resistant cells to GSDME pyroptosis driven by synthetic mRNAs, chemogenetic induction, and chemotherapy treatment. These results establish membrane cholesterol content as an endogenous checkpoint for gasdermin-mediated pyroptotic cell death during the execution phase, with implications for metabolic disease and cancer immunotherapy.